

Jiri Vencovsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2802271/publications.pdf>

Version: 2024-02-01

355
papers

32,236
citations

23567

58
h-index

4645

170
g-index

387
all docs

387
docs citations

387
times ranked

32272
citing authors

#	ARTICLE	IF	CITATIONS
1	Female Sexual Dysfunction and Pelvic Floor Muscle Function Associated with Systemic Sclerosis: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 612.	2.6	3
2	Hsp90 Levels in Idiopathic Inflammatory Myopathies and Their Association With Muscle Involvement and Disease Activity: A Cross-Sectional and Longitudinal Study. <i>Frontiers in Immunology</i> , 2022, 13, 811045.	4.8	2
3	MyomiRs in cultured muscle cells from patients with idiopathic inflammatory myopathy are modulated by disease but not by 6-month exercise training. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 346-357.	0.8	4
4	The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry. <i>Rheumatology International</i> , 2022, 42, 803-814.	3.0	3
5	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
6	MyomiRs in cultured muscle cells from patients with idiopathic inflammatory myopathy are modulated by disease but not by 6-month exercise training.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 346-357.	0.8	0
7	Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	5
8	Altered dynamics of lipid metabolism in muscle cells from patients with idiopathic inflammatory myopathy is ameliorated by 6Âmonths of training. <i>Journal of Physiology</i> , 2021, 599, 207-229.	2.9	2
9	The dysregulation of monocyte subpopulations in individuals at risk of developing rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 1823-1831.	1.9	4
10	Interleukin-35 in idiopathic inflammatory myopathies. <i>Cytokine</i> , 2021, 137, 155350.	3.2	3
11	Switching first-line targeted therapy after not reaching low disease activity within 6Âmonths is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry. <i>Arthritis Research and Therapy</i> , 2021, 23, 11.	3.5	5
12	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. <i>Scientific Reports</i> , 2021, 11, 1.	3.3	9,439
13	High miR-451 expression in peripheral blood mononuclear cells from subjects at risk of developing rheumatoid arthritis. <i>Scientific Reports</i> , 2021, 11, 4719.	3.3	7
14	S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils. <i>Scientific Reports</i> , 2021, 11, 6063.	3.3	17
15	Circulating miR-145 as a marker of therapeutic response to anti-TNF therapy in patients with ankylosing spondylitis. <i>Physiological Research</i> , 2021, 70, 255-264.	0.9	3
16	Sexual function in patients with idiopathic inflammatory myopathies: a cross-sectional study. <i>Rheumatology</i> , 2021, 60, 5060-5072.	1.9	6
17	Clinical Trials in Myositis: Where Do We Stand?. <i>Current Treatment Options in Rheumatology</i> , 2021, 7, 222-242.	1.4	0
18	Association of altered lipid profile with disease activity, duration, and glucocorticoid treatment in patients with idiopathic inflammatory myopathies. <i>European Journal of Preventive Cardiology</i> , 2021, 28, .	1.8	1

#	ARTICLE	IF	CITATIONS
19	The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. Autoimmunity Reviews, 2021, 20, 102797.	5.8	56
20	The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up. Arthritis Research and Therapy, 2021, 23, 173.	3.5	8
21	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines, 2021, 9, 650.	3.2	5
22	Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response. Scientific Reports, 2021, 11, 11525.	3.3	10
23	Polymyositis: does it really exist as a distinct clinical subset?. Current Opinion in Rheumatology, 2021, 33, 537-543.	4.3	13
24	Idiopathic inflammatory myopathies - new advances. Neurologie Pro Praxi, 2021, 21, 477-484.	0.1	0
25	Plasma heat shock protein 90 levels in patients with spondyloarthritis and their relation to structural changes: a cross-sectional study. Biomarkers in Medicine, 2021, 15, 5-13.	1.4	3
26	IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis. Frontiers in Immunology, 2021, 12, 745523.	4.8	11
27	Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis. Biomolecules, 2021, 11, 4.	4.0	5
28	Idiopathic inflammatory myopathies. Nature Reviews Disease Primers, 2021, 7, 86.	30.5	212
29	Clusterin is upregulated in serum and muscle tissue in idiopathic inflammatory myopathies and associates with clinical disease activity and cytokine profile. Clinical and Experimental Rheumatology, 2021, 39, 1021-1032.	0.8	1
30	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. Neuromuscular Disorders, 2020, 30, 70-92.	0.6	148
31	Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry. Expert Opinion on Biological Therapy, 2020, 20, 183-192.	3.1	5
32	Earlier cancer diagnosis after myositis onset is associated with improved long term survival: results from UK, French and Czech cohorts. Rheumatology, 2020, 59, .	1.9	0
33	AUTOIMMUNE MYOPATHIES. Neuromuscular Disorders, 2020, 30, S133.	0.6	0
34	Cytokines and inflammatory mediators as promising markers of polymyositis/dermatomyositis. Current Opinion in Rheumatology, 2020, 32, 534-541.	4.3	16
35	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. Annals of the Rheumatic Diseases, 2020, 79, 1423-1431.	0.9	11
36	How Imaging Can Assist with Diagnosis and Monitoring of Disease in Myositis. Current Rheumatology Reports, 2020, 22, 62.	4.7	7

#	ARTICLE	IF	CITATIONS
37	Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2020, 49, 361-370.	1.1	1
38	Alterations in activin Aâ€“myostatinâ€“follistatin system associate with disease activity in inflammatory myopathies. Rheumatology, 2020, 59, 2491-2501.	1.9	15
39	S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity. BMC Rheumatology, 2020, 4, 13.	1.6	1
40	Patients with Rheumatoid Arthritis Acquire Sustainable Skills for Home Monitoring: A Prospective Dual-country Cohort Study (ELECTOR Clinical Trial I). Journal of Rheumatology, 2020, 47, 658-667.	2.0	7
41	Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. Rheumatology, 2020, 59, 1026-1030.	1.9	16
42	SAT0324â€“SEXUAL HEALTH IN WOMEN AND MEN WITH SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY. Annals of the Rheumatic Diseases, 2020, 79, 1107.2-1108.	0.9	1
43	Elevated tenascin-C serum levels in patients with axial spondyloarthritis. Physiological Research, 2020, 69, 653-660.	0.9	4
44	FRI0041â€“ULTRASOUND-DETECTED SYNOVITIS AMONG INDIVIDUALS AT RISK OF RHEUMATOID ARTHRITIS INCREASES THE RISK OF DEVELOPING CLINICAL ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 595-596.	0.9	9
45	THU0365â€“INCREASED HSP90 IN MUSCLE TISSUE AND PLASMA ASSOCIATES WITH DISEASE ACTIVITY AND SKELETAL MUSCLE INVOLVEMENT IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. Annals of the Rheumatic Diseases, 2020, 79, 414.1-414.	0.9	0
46	FRI0002â€“S100A11 (CALGIZZARIN) IS RELEASED DURING NEUTROPHIL EXTRACELLULAR TRAPS FORMATION AND STIMULATES RELEASE OF IL-6 AND TNF IN RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 572.3-572.	0.9	0
47	AB1233â€“GENDER DIFFERENCE IN DISEASE SEVERITY AND TREATMENT OUTCOMES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS (RA), AXIAL SPONDYLOARTHRITIS (AXSPA) AND PSORIATIC ARTHRITIS (PSA) STARTING TREATMENT WITH TARGETED THERAPY IN THE CZECH REPUBLIC. Annals of the Rheumatic Diseases, 2020, 79, 1907.1-1908.	0.9	2
48	FRI0255â€“BODY COMPOSITION IN SCLERODERMA PATIENTS IS ASSOCIATED WITH DISEASE ACTIVITY, SERUM LEVELS OF INFLAMMATORY CYTOKINES AND PARAMETERS OF NUTRITION AND LIPID METABOLISM. Annals of the Rheumatic Diseases, 2020, 79, 711.3-712.	0.9	0
49	OP0135â€“INHIBITION OF HSP90 REDUCES PROGRESSION OF DERMAL FIBROSIS AND INDUCES REGRESSION OF ESTABLISHED EXPERIMENTAL DERMAL FIBROSIS INDUCED BY BLEOMYCIN. Annals of the Rheumatic Diseases, 2020, 79, 87-88.	0.9	0
50	SAT0627-HPRâ€“SEXUAL QUALITY OF LIFE IN 39 FEMALE PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. Annals of the Rheumatic Diseases, 2020, 79, 1273.2-1274.	0.9	0
51	AB0001â€“PLASMA miRNA PROFILE IN PATIENTS WITH HAND OSTEOARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 1305.1-1305.	0.9	0
52	OP0136â€“THE INFLUENCE OF LONG-TERM EXERCISE AND IN VITRO EXERCISE-MIMICKING STIMULATION ON THE PRODUCTION OF MYOKINES AND CYTOKINES IN MYOTUBES OF PATIENTS WITH CHRONIC IDIOPATHIC INFLAMMATORY MYOPATHIES. Annals of the Rheumatic Diseases, 2020, 79, 88.2-88.	0.9	0
53	OP0138â€“CLUSTERIN ASSOCIATES WITH DISEASE MECHANISMS AND INFLAMMATION IN MYOSITIS PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 89.2-89.	0.9	0
54	THU0358â€“NEGATIVE CHANGES OF BODY COMPOSITION IN MYOSITIS PATIENTS AND THEIR ASSOCIATION WITH DISEASE SPECIFIC CHARACTERISTICS, PHYSICAL ACTIVITY AND NUTRITIONAL STATUS.. Annals of the Rheumatic Diseases, 2020, 79, 410.3-410.	0.9	0

#	ARTICLE	IF	CITATIONS
55	FRI0262â€¦INCREASED PLASMA LEVELS OF HSP90 ARE ASSOCIATED WITH MORE SEVERE LUNG AND SKIN INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS. Annals of the Rheumatic Diseases, 2020, 79, 715-716.	0.9	0
56	Effect of CTLA4â€¦g (abatacept) treatment on T cells and B cells in peripheral blood of patients with polymyositis and dermatomyositis. Scandinavian Journal of Immunology, 2019, 89, e12732.	2.7	8
57	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. Annals of the Rheumatic Diseases, 2019, 78, 1472-1479.	0.9	7
58	Idiopathic Inflammatory Myopathies. Rheumatic Disease Clinics of North America, 2019, 45, 569-581.	1.9	41
59	Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis. Cytokine, 2019, 116, 13-20.	3.2	17
60	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Annals of the Rheumatic Diseases, 2019, 78, 996-1002.	0.9	81
61	Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Arthritis Research and Therapy, 2019, 21, 103.	3.5	61
62	Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. Journal of Autoimmunity, 2019, 101, 48-55.	6.5	184
63	Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study. Rheumatology International, 2019, 39, 1037-1043.	3.0	6
64	SAT0258â€¦SEXUAL HEALTH IMPAIRMENT IN WOMEN WITH SYSTEMIC SCLEROSIS. , 2019, , .		0
65	FRI0642â€¦USE OF MAGNETIC RESONANCE IMAGING FOR ASSESSMENT OF PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES â€” A SUBANALYSIS OF THE PROMETHEUS STUDY. , 2019, , .		1
66	P166â€¦Impact of disease activity, duration and muscle involvement on changes of body composition in myositis patients. , 2019, , .		0
67	P167â€¦Association of changes of body composition in scleroderma patients with disease activity, physical activity and serum levels of inflammatory cytokines. , 2019, , .		0
68	P171â€¦Hsp90 in axial spondyloarthritis, psoriatic arthritis and rheumatoid arthritis. , 2019, , .		0
69	P024â€¦Disturbed sexual functioning in female patients with idiopathic inflammatory myopathies. , 2019, , .		0
70	P025â€¦Disturbed sexual functioning in female patients with systemic sclerosis. , 2019, , .		0
71	P044â€¦Effect of specialized 6-month ADL training with subsequent a 6-month follow-up period in patients with myositis â€” preliminary data. , 2019, , .		0
72	P045â€¦Effect of specialized 6-month physical-occupational intervention with subsequent 6-month follow-up period in patients with scleroderma â€” preliminary data. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
73	AB0687â€¦EFFECTIVENESS OF SPECIALIZED AND INTENSIVE ADL TRAINING IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES â€“ PRELIMINARY RESULTS OF A ONE-YEAR CONTROLLED STUDY. , 2019, , .		0
74	FRI0107â€¦THE EFFECT OF CO-MEDICATION WITH METHOTREXATE OR OTHER CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON FIRST TUMOR NECROSIS INHIBITOR DRUG SURVIVAL IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE CZECH ATTRA REGISTRY. , 2019, , .		0
75	AB0676â€¦BODY COMPOSITION IN MYOSITIS PATIENTS AND THE ASSOCIATION WITH DISEASE SPECIFIC FEATURES, PHYSICAL ACTIVITY AND PLASMA LEVELS OF INFLAMMATORY CYTOKINES. , 2019, , .		0
76	OP0066â€¦EFFECTIVENESS OF SPECIALIZED HAND/FACE PHYSICAL-OCCUPATIONAL THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS â€“ PRELIMINARY RESULTS OF A ONE-YEAR CONTROLLED STUDY. , 2019, , .		0
77	THU0062â€¦THE DYSREGULATION OF NK CELLS AND NON-CLASSICAL AND CLASSICAL MONOCYTE SUBPOPULATIONS IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS. , 2019, , .		0
78	AB0660â€¦SEXUAL HEALTH IMPAIRMENT IN WOMEN WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. , 2019, , .		0
79	Arthritis in Idiopathic Inflammatory Myopathies. Current Rheumatology Reports, 2019, 21, 70.	4.7	10
80	Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study. Rheumatology International, 2019, 39, 469-478.	3.0	23
81	Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry. Clinical and Experimental Rheumatology, 2019, 37, 342-343.	0.8	8
82	S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. Clinical and Experimental Rheumatology, 2019, 37, 338-339.	0.8	1
83	Cigarette smoking and clinical response to certolizumab pegol treatment in Hungarian, Czech, and Slovak patients with rheumatoid arthritis: 104-week data from the CIMDORA prospective, non-interventional study. Clinical and Experimental Rheumatology, 2019, 37, 1010-1018.	0.8	1
84	Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. Clinical Rheumatology, 2018, 37, 2055-2062.	2.2	23
85	Efficacy and safety of trehalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. Annals of the Rheumatic Diseases, 2018, 77, 495-499.	0.9	10
86	Splicing variant of <i>WDFY4</i> augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Annals of the Rheumatic Diseases, 2018, 77, 602-611.	0.9	51
87	Mavrilimumab, a Fully Human Granulocyteâ€“Macrophage Colonyâ€“Stimulating Factor Receptor Î± Monoclonal Antibody. Arthritis and Rheumatology, 2018, 70, 679-689.	5.6	73
88	P082â€¦Circulating mir-145 as a marker of therapeutic response in patients with ankylosing spondylitis receiving anti-tnf therapy. , 2018, , .		0
89	P095â€¦Plasma levels of HSP90 are increased in patients with systemic sclerosis with more severe organ involvement. , 2018, , .		0
90	P091â€¦Clusterin is increased in early rheumatoid arthritis and predicts disease activity and treatment response. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
91	P058â€¦S100 proteins effectively discriminate systemic lupus erythematosus patients from healthy controls, but are not associated with measures of disease activity. , 2018, , .		0
92	P099â€¦Intensive 24-week physiotherapy programme in patients with idiopathic inflammatory myopathies â€“ preliminary data from a single-centre controlled study. , 2018, , .		0
93	Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Annals of the Rheumatic Diseases, 2018, 77, 55-62.	0.9	100
94	Phase <sc>III</sc> Randomized Study of <sc>SB</sc>5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderateâ€”Severe Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 40-48.	5.6	104
95	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Annals of the Rheumatic Diseases, 2018, 77, 30-39.	0.9	183
96	A Randomized Phase <sc>II</sc>b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 49-59.	5.6	76
97	SP0175â€¦Heterogeneity of myositis and therapeutic consequences. , 2018, , .		0
98	i054â€¦The long-term complications of non-fatal inflammatory muscle disease. Rheumatology, 2018, 57, .	1.9	0
99	Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain. BMC Musculoskeletal Disorders, 2018, 19, 264.	1.9	20
100	THU0184â€¦Impact of immunogenicity on clinical efficacy and administration related reaction in tn timerators: a pooled-analysis from three biosimilar studies in patients with rheumatoid arthritis. , 2018, , .		0
101	Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-Î³ autoantibodies in adult patients with myositis. Arthritis Research and Therapy, 2018, 20, 117.	3.5	16
102	Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis. Arthritis Research and Therapy, 2018, 20, 158.	3.5	23
103	AB0239â€¦Development of a novel â€“molecular disease activityâ€œ tool composed of 8 serum biomarkers for monitoring rheumatoid arthritis. , 2018, , .		0
104	Idiopathic inflammatory myopathies. Vnitri Lekarstvi, 2018, 64, 155-163.	0.2	1
105	AB0207â€¦Calprotectin (S100A8/9) plasma levels decrease after abatacept therapy and correlate with disease activity in patients with rheumatoid arthritis. , 2018, , .		0
106	SAT0483â€¦Female sexual dysfunction in patients with systemic sclerosis. , 2018, , .		0
107	AB0799â€¦Alterations of body composition in scleroderma patients are associated with disease activity and physical activity but not with lung involvement. , 2018, , .		0
108	THU0651â€¦The influence of age, gender, employment status, or education on the choice of bio-similar vs. bio-original variant of the same bdmard in patients with ra or as starting biological therapy â€“ real life data from the czech biologics registry attra. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
109	FRI0675â€¦Rabiopred, an innovative theranostic tool to assist clinicians select an optimal anti-tnf alpha biological therapy for rheumatoid arthritis patients. , 2018, , .		1
110	SAT0285â€¦Efficacy of early versus delayed initiation of anti-tnf-alpha treatment in axial spondyloarthritis. data from the czech registry attra. , 2018, , .		0
111	SAT0493â€¦Plasma levels of hsp90 are increased in interstitial lung disease and skin fibrosis in patients with systemic sclerosis. , 2018, , .		0
112	THU0399â€¦Female sexual dysfunction in patients with idiopathic inflammatory myopathies. , 2018, , .		0
113	AB0800â€¦Changes of body composition in myositis patients are associated with disease duration, inflammatory status, skeletal muscle involvement and physical activity. , 2018, , .		0
114	The role of imaging in evaluating patients with idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology, 2018, 36 Suppl 114, 74-81.	0.8	4
115	A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Annals of the Rheumatic Diseases, 2017, 76, 51-57.	0.9	201
116	Immuneâ€¦Array Analysis in Sporadic Inclusion Body Myositis Reveals HLAâ€¦DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. Arthritis and Rheumatology, 2017, 69, 1090-1099.	5.6	41
117	A randomised phase IIb study of mavrilimumab, a novel GMâ€¦CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1020-1030.	0.9	117
118	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 491-496.	0.9	209
119	International collaboration including patients is essential to develop new therapies for patients with myositis. Current Opinion in Rheumatology, 2017, 29, 234-240.	4.3	5
120	Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 79.	3.5	35
121	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 911-923.	5.6	59
122	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 898-910.	5.6	52
123	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis. Annals of the Rheumatic Diseases, 2017, 76, 792-801.	0.9	92
124	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis. Annals of the Rheumatic Diseases, 2017, 76, 782-791.	0.9	51
125	Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients. Rheumatology and Therapy, 2017, 4, 57-69.	2.3	11
126	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases, 2017, 76, 1955-1964.	0.9	754

#	ARTICLE	IF	CITATIONS
127	08.48â€¦Increased body fat but decreased lean body mass and bone mineral density in myositis patients are associated with disease duration, inflammatory status, skeletal muscle involvement and physical activity. , 2017, , .		0
128	THU0113â€¦Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal c-reactive protein. , 2017, , .		0
129	08.49â€¦Efficacy of an intensive 24-week physiotherapy programme in scleroderma patients â€“ preliminary data from a single-centre controlled study. , 2017, , .		0
130	FRI0399â€¦Efficacy of an intensive 24-week physiotherapy programme in patients with systemic sclerosis - preliminary data from a single-center controlled study. , 2017, , .		0
131	SAT0358â€¦Decreased body fat, lean body mass and bone mineral density in patients with systemic sclerosis are associated with disease activity and physical activity. , 2017, , .		0
132	52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. Rheumatology, 2017, 56, 2093-2101.	1.9	59
133	SAT0374â€¦The euromyositis registry: an international description of myositis. , 2017, , .		1
134	AB0387â€¦Comparison of etanercept in monotherapy and combination with synthetic dmards: data from attra registry. , 2017, , .		0
135	Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Annals of the Rheumatic Diseases, 2017, 76, 1986-1991.	0.9	90
136	02.37â€¦IL-37 is associated with increased atherogenesis rather than disease activity in patients with rheumatoid arthritis. , 2017, , .		0
137	MRI scoring methods used in evaluation of muscle involvement in patients with idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2017, 29, 623-631.	4.3	23
138	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open, 2017, 3, e000507.	3.8	115
139	OP0204â€¦Impact of anti-drug antibody and injection site reaction on efficacy: 24-week results from a phase iii study comparing SB4 (etanercept biosimilar) with reference etanercept in patients with rheumatoid arthritis. , 2017, , .		0
140	Idiopathic inflammatory myopathies â€“ increased expression of heat shock protein-90 in muscle tissue and plasma correlates with disease activity and skeletal muscle involvement. Neuromuscular Disorders, 2017, 27, S157.	0.6	0
141	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis and Rheumatology, 2017, 69, 2271-2282.	5.6	391
142	Interleukin-20 is triggered by TLR ligands and associates with disease activity in patients with rheumatoid arthritis. Cytokine, 2017, 97, 187-192.	3.2	10
143	Response to: â€“Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteriaâ€™ by Cavagna et al. Annals of the Rheumatic Diseases, 2017, 77, annrheumdis-2017-212382.	0.9	2
144	SAT0169â€¦Maintenance and improvement in clinical efficacy between week 12 and 24 in patients with rheumatoid arthritis treated with sb4 or reference etanercept. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
145	08.01â€¦Heat shock protein 90 is increased in muscle tissue and plasma in idiopathic inflammatory myopathies. , 2017, , .		0
146	08.47â€¦Decreased body fat, lean body mass and bone mineral density in scleroderma patients are associated with disease activity and physical activity. , 2017, , .		0
147	THU0621â€¦Comparison of the effect of ANTI-TNF therapy on work disability between patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis over one yearâ€œ real life data from the czech biologics registry attra. , 2017, , .		0
148	AB0671â€¦Increased body fat but decreased lean body mass and bone mineral density in patients with idiopathic inflammatory myopathies are associated with disease duration, inflammatory status, skeletal muscle involvement and physical activity. , 2017, , .		0
149	THU0027â€¦Clusterin is elevated in serum and muscle tissue in idiopathic inflammatory myopathies and is associated with disease activity. , 2017, , .		0
150	02.39â€¦Clusterin is increased in idiopathic inflammatory myopathies and is associated with disease activity. , 2017, , .		0
151	FRI0216â€¦Results of a longitudinal review of pulmonary function and safety data in a phase iib clinical programme testing granulocyte-macrophage colony-stimulating factor (GMâ€œCSF) receptor antagonist mavrilimumab for treatment of rheumatoid arthritis (RA). , 2017, , .		0
152	THU0058â€¦S100A11 protein is up-regulated in patients with idiopathic inflammatory myopathies and is associated with disease activity. , 2017, , .		0
153	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteriaâ€œmethodological aspects. Rheumatology, 2017, 56, 1884-1893.	1.9	33
154	THU0650â€¦The effect of anti-tnf therapy on work productivity and activity impairment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis over one year â€œ real life data from the czech biologics registry attra. , 2017, , .		0
155	AB0653â€¦Efficacy of an intensive 24-week physiotherapy programme in myositis patients - preliminary data from a single-center controlled study. , 2017, , .		0
156	Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis. PLoS ONE, 2017, 12, e0185323.	2.5	30
157	Opportunities and challenges in rheumatology research in Central Europe. Arthritis Research and Therapy, 2017, 19, 196.	3.5	3
158	02.30â€¦High levels of mir-451a differentiate patients with clinically suspect arthralgia from healthy controls. , 2017, , .		0
159	AB1034â€¦Scoring systems of muscle mri in idiopathic inflammatory myopathies. , 2017, , .		0
160	Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. PLoS ONE, 2017, 12, e0183420.	2.5	32
161	A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1â€œyear: a propensity score-matched cohort study. Annals of the Rheumatic Diseases, 2016, 75, 96-102.	0.9	61
162	A3.10â€¦Serum calprotectinis elevated in patients with early rheumatoid arthritis but not in patients at risk of developing rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, A36.1-A36.	0.9	0

#	ARTICLE	IF	CITATIONS
163	AB0952â€¦Serum Visfatin and Resistin, but Not Adiponectin or Leptin, Are Associated with Ultrasound Synovitis in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1227.1-1227.	0.9	0
164	FRI0216â€¦Long-Term Safety and Efficacy of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 510.1-510.	0.9	1
165	A9.02â€¦Heat shock protein 90 plasma levels correlate with disease activity, skeletal muscle, lung and heart involvement in idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A70.2-A71.	0.9	0
166	Expression and Regulation of PIWI-Proteins and PIWI-Interacting RNAs in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0166920.	2.5	22
167	Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies. <i>Scandinavian Journal of Immunology</i> , 2016, 84, 100-109.	2.7	30
168	Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e65-e65.	0.9	9
169	SAT0146â€¦Earth Explorer 2, A Phase IIB Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, and The Tumor Necrosis Factor Antagonist Golimumab in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 717.2-718.	0.9	2
170	Response to: â€˜Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another considerationâ€™ by Marshall et al. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e38-e38.	0.9	7
171	THU0150â€¦Long-Term Safety and Efficacy of SB4 (Etanercept Biosimilar) in Patients with Rheumatoid Arthritis: Comparison between Continuing SB4 and Switching from Etanercept Reference Product To SB4. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 236.1-236.	0.9	11
172	Response to: â€˜Lower anti-drug antibodies with etanercept biosimilar: Can C trough explain the differencesâ€™ by Shah. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e61-e61.	0.9	1
173	Anti-HMCCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. <i>Autoimmunity Reviews</i> , 2016, 15, 983-993.	5.8	105
174	Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , 2016, 18, 156.	3.5	4
175	Confirmation on the immunogenicity assay used in the SB4 phase III study: response to the comments by Meacci et al. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e40-e40.	0.9	9
176	A6.12â€¦Physiological evidence for diversification of IFNÎ±- and IFNÎ²-mediated response programs in different autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A52.1-A52.	0.9	0
177	A9.04â€¦SNPs in the baf gene are associated with increased risk of anti-jo-1-positivity and high serum baf levels in patients with myositis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A71.2-A72.	0.9	0
178	A10.17â€¦Interleukin-20 serum levels correlate with disease activity in rheumatoid arthritis patients and decrease in response to rituximab treatment. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A79.2-A79.	0.9	0
179	SAT0068â€¦Circulating MIR-126 Is A Marker of Disease Activity in Patients with Early RA but Does Not Differentiate Patients at Risk of Developing RA. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 689.2-689.	0.9	0
180	Response to: â€˜Reporting of potential immunogenicity with biologic drugs: clarity and accuracy requiredâ€™ by Moots et al. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e25-e25.	0.9	5

#	ARTICLE	IF	CITATIONS
181	A8.06â€¦Microna-125b expression in PBMCS is inversely associated with disease activity in patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, A67.1-A67.	0.9	0
182	AB0599â€¦Interleukin-35 in Idiopathic Inflammatory Myopathies. Annals of the Rheumatic Diseases, 2016, 75, 1109.2-1109.	0.9	0
183	SP0163â€¦What Is New: Idiopathic Inflammatory Myopathies. Annals of the Rheumatic Diseases, 2016, 75, 40.2-40.	0.9	0
184	Physiological evidence for diversification of IFNÎ±- and IFNÎ²-mediated response programs in different autoimmune diseases. Arthritis Research and Therapy, 2016, 18, 49.	3.5	32
185	MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis. Arthritis Research and Therapy, 2016, 18, 124.	3.5	48
186	Disease specificity of autoantibodies to cytosolic 5â€²-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Annals of the Rheumatic Diseases, 2016, 75, 696-701.	0.9	116
187	The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Annals of the Rheumatic Diseases, 2016, 75, 795-810.	0.9	780
188	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Annals of the Rheumatic Diseases, 2016, 75, 1558-1566.	0.9	127
189	Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. PLoS ONE, 2016, 11, e0165498.	2.5	14
190	SAT0240â€¦Snps in The Baff Gene Are Associated with Increased Risk of Anti-Jo-1-Positivity and High Serum BAFF Levels in Patients with Myositis. Annals of the Rheumatic Diseases, 2016, 75, 755.2-755.	0.9	0
191	Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients. Clinical and Experimental Rheumatology, 2016, 34, 222-9.	0.8	2
192	OP0034â€¦Efficacy and Safety of Mavrilimumab, A Fully Human Gmâ€²CSFR-Alpha Monoclonal Antibody in Patients with Rheumatoid Arthritis: Primary Results from the Earth Explorer 1 Study. Annals of the Rheumatic Diseases, 2015, 74, 78.1-78.	0.9	0
193	THU0056â€¦Expression of Piwi-interacting RNA in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 212.2-212.	0.9	0
194	SAT0436â€¦Abatacept in the Treatment of Adult Dermatomyositis and Polymyositis: Artemis, a Randomized, Treatment Delayed-Start Trial. Annals of the Rheumatic Diseases, 2015, 74, 817.3-818.	0.9	3
195	FRI0128â€¦A Phase III Randomised, Double-Blind Clinical Study Comparing SB4, An Etanercept Biosimilar, With Etanercept Reference Product (EnbrelÂ®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-Week Results). Annals of the Rheumatic Diseases, 2015, 74, 467.2-468.	0.9	3
196	SP0175â€¦New ACR/EULAR Response Criteria for Myositis. Annals of the Rheumatic Diseases, 2015, 74, 42.5-43.	0.9	0
197	Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis Research and Therapy, 2015, 17, 245.	3.5	22
198	Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study. Arthritis Research and Therapy, 2015, 17, 341.	3.5	14

#	ARTICLE	IF	CITATIONS
199	A2.33â€¦Haplotype TTTT in the BAFF gene is associated with idiopathic inflammatory myopathies in HLA-DRB1*03 negative patients. Annals of the Rheumatic Diseases, 2015, 74, A29.2-A29.	0.9	0
200	SAT0189â€¦Rapid Onset of Clinical Benefit in Patients with RA Treated with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GMâ€¦CSFR-ALPHA: Subanalysis of the Phase IIB Earth Explorer 1 Study. Annals of the Rheumatic Diseases, 2015, 74, 723.3-724.	0.9	0
201	A6.26â€¦Analysis of circulating mirnas in patients with axial sponyloarthritis with different spinal involvement. Annals of the Rheumatic Diseases, 2015, 74, A66.1-A66.	0.9	1
202	FRI0435â€¦Interleukin-35 is Overexpressed in Systemic Sclerosis and its Serum Levels are Elevated in Early Disease. Annals of the Rheumatic Diseases, 2015, 74, 584.3-585.	0.9	0
203	A3.10â€¦Plasma levels of heat shock protein 90 correlate with disease activity, lung involvement and skin fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, A35.1-A35.	0.9	1
204	SAT0456â€¦Heat Shock Protein 90 Plasma Levels Correlate with Disease Activity, Lung Involvement and Skin Fibrosis in Systemic Sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 825.3-826.	0.9	0
205	SAT0250â€¦A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective and Less Costly Than Standard Dosing in Patients with Ankylosing Spondylitis Over Two Years: A Propensity Score-Matched Cohort Study. Annals of the Rheumatic Diseases, 2015, 74, 749.2-749.	0.9	2
206	FRI0592â€¦Serum Calprotectin is Associated with Ultrasound-Determined Active Synovitis in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 642.2-642.	0.9	0
207	Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis. Mediators of Inflammation, 2015, 2015, 1-6.	3.0	34
208	THU0127â€¦Development of Draft Criteria for Arthralgia that is Clinically Suspect for Progression to Rheumatoid Arthritis; Results of Phase 1. Annals of the Rheumatic Diseases, 2015, 74, 240.1-240.	0.9	1
209	Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 252.	3.5	60
210	Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis. Cytokine, 2015, 73, 36-43.	3.2	44
211	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. Rheumatology, 2015, 54, kev260.	1.9	17
212	OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Annals of the Rheumatic Diseases, 2015, 74, 2123-2129.	0.9	39
213	High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort. Biomarkers, 2015, 20, 47-51.	1.9	12
214	The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region. RMD Open, 2015, 1, e000044-e000044.	3.8	14
215	Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. Rheumatology, 2015, 54, 2010-2014.	1.9	55
216	Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes and Immunity, 2015, 16, 470-480.	4.1	103

#	ARTICLE	IF	CITATIONS
217	Dr. Vencovsky et al reply. Journal of Rheumatology, 2015, 42, 1061.2-1061.	2.0	0
218	Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. Journal of Clinical Investigation, 2015, 125, 4612-4624.	8.2	33
219	Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0132674.	2.5	28
220	Decreased Circulating Visfatin Is Associated with Improved Disease Activity in Early Rheumatoid Arthritis: Data from the PERAC Cohort. PLoS ONE, 2014, 9, e103495.	2.5	25
221	AB0075â€¦Calgizzarin (S100A11) is Up-Regulated in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 829.1-829.	0.9	0
222	THU0528â€¦Decrease in Circulating Visfatin Levels is Associated with Disease Activity Improvement in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 366.1-366.	0.9	1
223	A1.48â€¦Enhanced expression of CD11c on non-classical CD16+ peripheral blood monocytes in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, A20.2-A21.	0.9	1
224	SAT0349â€¦A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective, but Substantially Less Costly than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Matched Observational Study: Table 1. Annals of the Rheumatic Diseases, 2014, 73, 719.1-719.	0.9	1
225	Arthritis in Idiopathic Inflammatory Myopathy: Clinical Features and Autoantibody Associations. Journal of Rheumatology, 2014, 41, 1133-1139.	2.0	23
226	The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies. Arthritis Research and Therapy, 2014, 16, 468.	3.5	13
227	FRI0543â€¦Pregnancy Outcome in Adult Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents. Annals of the Rheumatic Diseases, 2014, 73, 583.2-583.	0.9	1
228	Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1898-1904.	0.9	165
229	Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?. Annals of the Rheumatic Diseases, 2014, 73, 2010-2021.	0.9	90
230	The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure) Tj ETQq0 0 0 rg13/Overlook 10 Tf 50	0.9	1
231	Genotyping of immune-related genetic variants identifies<i>TYK2</i> as a novel associated locus for idiopathic inflammatory myopathies. Annals of the Rheumatic Diseases, 2014, 73, 1750-1752.	0.9	25
232	A3.30â€¦Plasma level of HSP70 protein is increased in czech patients with idiopathic inflammatory myopathy. Annals of the Rheumatic Diseases, 2014, 73, A54.1-A54.	0.9	1
233	Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. Arthritis Research and Therapy, 2014, 16, 454.	3.5	25
234	Pregnancy Outcome in Idiopathic Inflammatory Myopathy Patients in a Multicenter Study. Journal of Rheumatology, 2014, 41, 2492.2-2494.	2.0	27

#	ARTICLE	IF	CITATIONS
235	Therapy of myositis. Current Opinion in Rheumatology, 2014, 26, 704-711.	4.3	39
236	Inflammatory myopathy associated with statins: report of three cases. Modern Rheumatology, 2014, 24, 366-371.	1.8	7
237	The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis. Rheumatology, 2014, 53, 1520-1526.	1.9	72
238	OP0289â€¦A Prospective, Randomized, Open-Label, Assessor-Blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids versus Glucocorticoids Alone in Patients with Polymyositis and Dermatomyositis (Prometheus Trial). Annals of the Rheumatic Diseases, 2014, 73, 171.1-171.	0.9	3
239	OP0235â€¦Genetic Risk Factors in Idiopathic Inflammatory Myopathies Are Shared with Other Autoimmune Disorders in European Populations. Annals of the Rheumatic Diseases, 2014, 73, 151.1-151.	0.9	0
240	FRI0520â€¦Association Study of the BAFF Genetic Variations in Two Independent Cohorts with Idiopathic Inflammatory Myopathies. Annals of the Rheumatic Diseases, 2014, 73, 575.3-576.	0.9	0
241	AB0009â€¦Association of MHC Haplotypes with Idiopathic Inflammatory Myopathy in Cohort of Czech Patients. Annals of the Rheumatic Diseases, 2014, 73, 806.3-806.	0.9	0
242	AB0163â€¦Comprehensive Analysis of Circulating Mirnas in Patients with Axial Spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 856.4-857.	0.9	0
243	SAT0565â€¦The Expression and Regulation of the Argonaute Protein Family Member PIWIL4 in RA. Annals of the Rheumatic Diseases, 2014, 73, 795.1-795.	0.9	0
244	A3.29â€¦Micro-RNA molecules are clearly involved in pathogenesis of idiopathic inflammatory myopathy. Annals of the Rheumatic Diseases, 2014, 73, A53.3-A54.	0.9	1
245	Decrease in Serum Interleukin-21 Levels Is Associated With Disease Activity Improvement in Patients With Recent-Onset Rheumatoid Arthritis. Physiological Research, 2014, 63, 475-481.	0.9	14
246	Investigation of idiopathic inflammatory myopathy for shared genetic risk factors with other autoimmune diseases: results from the European Myositis Network. Lancet, The, 2013, 381, S56.	13.7	0
247	The Role of Resistin in Inflammatory Myopathies. Current Rheumatology Reports, 2013, 15, 336.	4.7	15
248	The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels. Cytokine, 2013, 64, 441-447.	3.2	19
249	Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus. Rheumatology International, 2013, 33, 259-263.	3.0	36
250	Genomeâ€¦Wide Association Study of Dermatomyositis Reveals Genetic Overlap With Other Autoimmune Disorders. Arthritis and Rheumatism, 2013, 65, 3239-3247.	6.7	113
251	A10.3â€¦Arthritis in Patients with Idiopathic Inflammatory Myopathies. Annals of the Rheumatic Diseases, 2013, 72, A72.2-A72.	0.9	1
252	A7.7â€¦Different Genetic Background of Dermatomyositis and Polymyositis in a Single Centre Cohort. Annals of the Rheumatic Diseases, 2013, 72, A50.2-A50.	0.9	0

#	ARTICLE	IF	CITATIONS
253	FRIO030â€...Higher levels of serum interleukin-20 are associated with better response to disease-modifying antirheumatic drugs in patients with recent-onset rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 71, 319.3-320.	0.9	0
254	SAT0188â€...Clinical and Ultrasonographic Characteristics of Arthritis in Patients with Idiopathic Inflammatory Myopathies. Annals of the Rheumatic Diseases, 2013, 72, A644.3-A645.	0.9	1
255	FRIO186â€...Long-term safety and efficacy of 4-weekly certolizumab pegol monotherapy and combination therapy in rheumatoid arthritis: 5-year results from an open-label extension study. Annals of the Rheumatic Diseases, 2013, 72, A435.1-A435.	0.9	3
256	A7.11â€...Genetic Variation in Promoter Sequence of B-Cell-Activating Factor of the TNF Family (BAFF) in Patients with Idiopathic Inflammatory Myopathies (IIM). Annals of the Rheumatic Diseases, 2013, 72, A51.3-A52.	0.9	2
257	THU0232â€...Pregnancy outcome in idiopathic inflammatory myopathy patients in a multicenter study. Annals of the Rheumatic Diseases, 2013, 71, 233.3-234.	0.9	0
258	SAT0001â€...IFN signature is associated with autoantibody profiles in patients with myositis. Annals of the Rheumatic Diseases, 2013, 71, 471.1-471.	0.9	0
259	SAT0023â€...Investigation of idiopathic inflammatory myopathy for shared genetic risk factors with other autoimmune disorders: Results of UK myonet. Annals of the Rheumatic Diseases, 2013, 71, 478.3-479.	0.9	0
260	SAT0031â€...Anti-RO52 autoantibody epitope mapping in european cohort of myositis patients. Annals of the Rheumatic Diseases, 2013, 71, 481.2-481.	0.9	0
261	SAT0105â€...Circulating MIR-223 is downregulated in SERA of patients with early RA after treatment with methotrexate. Annals of the Rheumatic Diseases, 2013, 71, 506.1-506.	0.9	0
262	A4.15â€...Serum Levels of Visfatin and B-Cell Activating Factor of the TNF Family Correlate with Disease Activity in Patients with Myositis. Annals of the Rheumatic Diseases, 2013, 72, A29.2-A29.	0.9	0
263	A7.3â€...Association of Circulating miR-223 and miR-16 with Disease Activity in Patients with Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A48.3-A49.	0.9	0
264	A7.24â€...The Pentanucleotide Insertion in HSPA1B Gene is Associated with Idiopathic Inflammatory Myopathy. Annals of the Rheumatic Diseases, 2013, 72, A56.2-A56.	0.9	1
265	FRIO077â€...Levels of mir-16 in serum associate with response to therapy in patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, A395.1-A395.	0.9	0
266	A4.4â€...Circulating Metastasis Promoting Protein S100A4 in Idiopathic Inflammatory Myopathies. Annals of the Rheumatic Diseases, 2013, 72, A24.3-A25.	0.9	0
267	THU0253â€...ANTI-PM-SCL autoantibodies in polymyositis and dermatomyositis. Annals of the Rheumatic Diseases, 2013, 71, 240.2-240.	0.9	1
268	SAT0151â€...Long-term safety of 4-weekly certolizumab pegol in rheumatoid arthritis: 5 year results from an open label extension study:. Annals of the Rheumatic Diseases, 2013, 71, 523.1-523.	0.9	1
269	The expression profile of miR-23b is not altered in peripheral blood mononuclear cells of patients with idiopathic inflammatory myopathies. F1000Research, 2013, 2, 223.	1.6	2
270	Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents. Clinical and Experimental Rheumatology, 2013, 31, 111-7.	0.8	17

#	ARTICLE	IF	CITATIONS
271	Inflammatory myopathy associated with statins: report of three cases. <i>Modern Rheumatology</i> , 2012, , 1.	1.8	0
272	Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 961-965.	0.9	100
273	Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. <i>Rheumatology</i> , 2012, 51, 1226-1234.	1.9	66
274	Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 71-74.	0.9	55
275	European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 4-12.	0.9	405
276	Anti-PL-7 (Anti-Threonyl-tRNA Synthetase) Antisynthetase Syndrome. <i>Medicine (United States)</i> , 2012, 91, 206-211.	1.0	98
277	Anti-Ro52 epitope mapping in inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A50.1-A50.	0.9	0
278	IFN signature is associated with autoantibody profiles in patients with myositis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A49.1-A49.	0.9	0
279	Metastasis-inducing S100A4 protein is associated with treatment response in patients with recent-onset rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A15.2-A15.	0.9	0
280	Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. <i>Cytokine</i> , 2012, 58, 165-168.	3.2	29
281	Resistin in idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , 2012, 14, R111.	3.5	21
282	International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. <i>Arthritis Research and Therapy</i> , 2012, 14, R2.	3.5	19
283	No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2012, 31, 67-71.	2.2	18
284	Pentosidine, an Advanced Glycation End-Product, May Reflect Clinical and Morphological Features of Hand Osteoarthritis. <i>Open Rheumatology Journal</i> , 2012, 6, 64-69.	0.2	6
285	Novel Adipokine Fibroblast Growth Factor 21 Is Increased in Rheumatoid Arthritis. <i>Physiological Research</i> , 2012, 61, 489-494.	0.9	23
286	Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, R122.	3.5	69
287	The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. <i>Cytokine</i> , 2011, 55, 116-121.	3.2	31
288	Clinical trials roundup in idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2011, 23, 605-611.	4.3	9

#	ARTICLE	IF	CITATIONS
289	Adipokine profile is modulated in subcutaneous adipose tissue by TNF α inhibitors in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2054-2056.	0.9	9
290	The expression regulation of the HSPA1B gene in patients with myositis is not dependent on the presence of HLA-DRB1*03 risk allele. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A19-A20.	0.9	1
291	Modulation of subcutaneous adipose tissue adipokines by TNF- α blockade therapy in patients with inflammatory arthritides. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A85-A85.	0.9	0
292	Serum levels of interferon α do not correlate with disease activity in patients with dermatomyositis/polymyositis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 879-880.	0.9	17
293	The metastasis promoting protein S100A4 is increased in idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2011, 50, 1766-1772.	1.9	35
294	Potential role of S100A4 in an immune response of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A85-A85.	0.9	0
295	Serum levels of IFN- α do not correlate with disease activity in patients with dermatomyositis/polymyositis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A89-A90.	0.9	0
296	Delays in assessment of patients with rheumatoid arthritis: variations across Europe. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1822-1825.	0.9	112
297	Interrater reliability and aspects of validity of the myositis damage index. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1272-1276.	0.9	21
298	Polymorphism of the extrapituitary prolactin promoter and systemic sclerosis. <i>Rheumatology International</i> , 2010, 30, 1691-1693.	3.0	10
299	Treatment-resistant inflammatory myopathy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 427-440.	3.3	10
300	CD161 receptor participates in both impairing NK cell cytotoxicity and the response to glycans and vimentin in patients with rheumatoid arthritis. <i>Clinical Immunology</i> , 2010, 136, 139-147.	3.2	9
301	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010, 62, 2582-2591.	6.7	246
302	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
303	Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. <i>Arthritis and Rheumatism</i> , 2010, 62, 3154-3160.	6.7	60
304	Increased serum concentration of immune cell derived microparticles in polymyositis/dermatomyositis. <i>Immunology Letters</i> , 2010, 128, 124-130.	2.5	35
305	Myositis associated autoantibodies detected using a novel recombinant protein blotting: clinical associations. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A9-A10.	0.9	1
306	Genetic variation in promoter sequence of B cell-activating factor gene is associated with increased risk of myositis development. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A31-A31.	0.9	0

#	ARTICLE	IF	CITATIONS
307	Metastasis-Promoting protein S100A4 (MTS1) upregulates production of proinflammatory cytokines via TLR-4. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A38-A39.	0.9	0
308	Immune cell-derived microparticles in polymyositis/dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A55-A56.	0.9	0
309	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.9	2,994
310	Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1410-1411.	0.9	94
311	Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1285-1289.	0.9	59
312	Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 805-811.	0.9	290
313	Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 797-804.	0.9	424
314	Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 836-843.	0.9	95
315	Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis. <i>Rheumatology</i> , 2009, 48, 1590-1594.	1.9	40
316	Prospective new biological therapies for rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2009, 9, 102-107.	5.8	119
317	Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. <i>Clinical and Experimental Rheumatology</i> , 2009, 27, 958-63.	0.8	47
318	Reliability and validity of the myositis disease activity assessment tool. <i>Arthritis and Rheumatism</i> , 2008, 58, 3593-3599.	6.7	76
319	The role of MRI in the assessment of polymyositis and dermatomyositis. <i>Rheumatology</i> , 2007, 46, 1174-1179.	1.9	187
320	Quantiferon-TB Gold test in screening for latent tuberculosis before and during antitumour necrosis factor treatment. <i>Arthritis Research and Therapy</i> , 2007, 9, P33.	3.5	1
321	Endogenous HLA-DR-restricted presentation of the cartilage antigens human cartilage gp-39 and melanoma inhibitory activity in the inflamed rheumatoid joint. <i>Arthritis and Rheumatism</i> , 2007, 56, 2150-2159.	6.7	21
322	Advanced glycation end product pentosidine is not a relevant marker of disease activity in patients with rheumatoid arthritis. <i>Physiological Research</i> , 2007, 56, 771-777.	0.9	11
323	Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment. <i>Clinical and Experimental Rheumatology</i> , 2007, 25, 540-5.	0.8	10
324	Rheumatoid arthritis: the goal rather than the health-care provider is key. <i>Lancet</i> , The, 2006, 367, 450-452.	13.7	13

#	ARTICLE	IF	CITATIONS
325	Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1635-1638.	0.9	289
326	Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 α antigen. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 242-245.	0.9	124
327	A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 64-69.	0.9	90
328	The importance of cell surface RANKL in rheumatoid arthritis. <i>Arthritis Research</i> , 2005, 7, P152.	2.0	0
329	Title is missing!. <i>Arthritis Research</i> , 2005, 7, P149.	2.0	0
330	International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. <i>Rheumatology</i> , 2004, 43, 49-54.	1.9	311
331	Therapeutic strategies in polymyositis and dermatomyositis. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2004, 1, 369-374.	0.5	2
332	The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis. <i>Clinical and Experimental Rheumatology</i> , 2004, 22, 395-402.	0.8	9
333	Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 427-430.	0.9	232
334	Title is missing!. <i>Arthritis Research</i> , 2003, 5, 119.	2.0	0
335	Polymorphism in the immunoglobulin VH gene V1-69 affects susceptibility to rheumatoid arthritis in subjects lacking the HLA-DRB1 shared epitope. <i>British Journal of Rheumatology</i> , 2002, 41, 401-410.	2.3	21
336	Tumour necrosis factor $\hat{I}\pm$ G $\hat{A}\hat{T}$ 'A $\hat{A}\sim$ 238 and G $\hat{A}\hat{T}$ 'A $\hat{A}\sim$ 308 polymorphisms in juvenile idiopathic arthritis. <i>Rheumatology</i> , 2002, 41, 223-227.	1.9	74
337	Higher frequency of allele 2 of the interleukin-1 receptor antagonist gene in patients with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 2387-2391.	6.7	43
338	Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. <i>British Journal of Rheumatology</i> , 2001, 40, 1262-1273.	2.3	270
339	Autoantibody profiles in the sera of European patients with myositis. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 116-123.	0.9	330
340	Immunological investigation in children with juvenile chronic arthritis. <i>Medical Science Monitor</i> , 2001, 7, 99-104.	1.1	6
341	The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 141-142.	0.9	97
342	Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. <i>Scandinavian Journal of Rheumatology</i> , 2000, 29, 95-102.	1.1	174

#	ARTICLE	IF	CITATIONS
343	Identification of common epitopes on gliadin, enterocytes, and calreticulin recognised by anti gliadin antibodies of patients with coeliac disease. <i>Gut</i> , 1999, 44, 168-173.	12.1	43
344	Primary Sjögren's syndrome in children and adolescents: proposal for diagnostic criteria. <i>Clinical and Experimental Rheumatology</i> , 1999, 17, 381-6.	0.8	67
345	IL-10 Gene Promoter Polymorphisms in Rheumatoid Arthritis: SHORT REPORT. <i>Scandinavian Journal of Rheumatology</i> , 1998, 27, 142-145.	1.1	152
346	Effect of 1 year cyclosporine a treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. <i>Lupus</i> , 1998, 7, 29-36.	1.6	59
347	Somatic Mutation and CDR3 Length of Immunoglobulin Lambda Variable Region Genes in the Synovium of Patients with Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 1997, 815, 319-323.	3.8	2
348	Immunoglobulin Variable Region (IgV) Gene Expression in Rheumatoid Factors from Monozygotic Twins with Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 1997, 815, 324-326.	3.8	1
349	Heterogenous nuclear RNP C1 and C2 core proteins are targets for an autoantibody found in the serum of a patient with systemic sclerosis and psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 1997, 40, 2172-2177.	6.7	28
350	Monozygotic Rheumatoid Arthritis Twin Pairs Express Similar Levels of Conserved Immunoglobulin V Gene in Polyclonal Rheumatoid Factors Irrespective of Disease Status. <i>Scandinavian Journal of Immunology</i> , 1995, 42, 147-157.	2.7	7
351	HETEROGENEITY OF DISEASE PHENOTYPE IN MONOZYGOTIC TWINS CONCORDANT FOR RHEUMATOID ARTHRITIS. <i>Rheumatology</i> , 1995, 34, 215-220.	1.9	17
352	RHEUMATOID FACTORS AND GERMLINE GENES IN RHEUMATOID ARTHRITIS: EVIDENCE OF AN INTRINSIC B-LYMPHOCYTE DEFECT?. <i>Rheumatology</i> , 1994, 33, 105-107.	1.9	5
353	Clinical associations of IgG antibodies to the ribonucleoprotein p67 polypeptide in patients with systemic lupus erythematosus.. <i>Annals of the Rheumatic Diseases</i> , 1992, 51, 1313-1317.	0.9	4
354	Clinical-morphological correlation of polymyositis and dermatomyositis. <i>Scandinavian Journal of Rheumatology</i> , 1988, 17, 32-35.	1.1	3
355	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1